In this article:

Maxim Group Thinks Capricor Therapeutics’ Stock is Going to Recover

In this article:
In this article:

Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPRResearch Report) yesterday and set a price target of $12.00. The company’s shares closed last Wednesday at $3.34, close to its 52-week low of $2.56.

According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -21.5% and a 13.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Capricor Therapeutics with a $13.00 average price target.

See today’s best-performing stocks on TipRanks >>

Capricor Therapeutics’ market cap is currently $83.07M and has a P/E ratio of -4.22.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Read More on CAPR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed